Status:
COMPLETED
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
Lead Sponsor:
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions:
Diarrhea
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.
Detailed Description
This is a dose-finding study to select a safe and efficacious dose of OPT-80. Patients will be evaluated for safety and efficacy and pharmacokinetic parameters will be investigated.
Eligibility Criteria
Inclusion
- Patients with CDAD
Exclusion
- Patients with severe CDAD
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00097422
Start Date
November 1 2004
End Date
April 1 2005
Last Update
March 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Biologics
New Hope, Pennsylvania, United States, 18938